Wednesday, February 10, 2010, 10:40AM AEST - The Australian Stockmarket closes in 5 hours and 25 minutes.
To create a watchlist or portfolio of shares, Register

XOMA Ltd. (XOMA)

8:00AM AEST: 0.415 USD  Down 0.015 (3.49%)  
 MORE ON XOMA 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 XOMA Ltd. (NGM:XOMA) Delayed quote dataEdit
Last Trade:0.415 USD
Trade Time: 8:00AM AEST
Change:Down 0.015 (3.49%)
Prev Close:0.43
Open:0.445
Bid:0.419 x 10000
Ask:0.435 x 7500
1y Target Est:2.73
Day's Range:0.415 - 0.45
52wk Range:0.37 - 1.34
Volume:3,908,875
Avg Vol (3m):3,054,470
Market Cap:82.56M
P/E (ttm):8.14
EPS (ttm):0.051
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add XOMA to Portfolio   Download Data

 HEADLINES 
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
GlobeNewswire (Tue 11:00PM)
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
GlobeNewswire (Thu, Feb 4)
XOMA LTD /DE/ Files SEC form 8-K/A, Financial Statements and Exhibits
EDGAR Online (Thu, Feb 4)
Liberty Analytics Co. Initiates Independent Research Coverage on XOMA Ltd.
GlobeNewswire (Thu, Feb 4)
Xoma to raise $21M via stock, warrants
at bizjournals.com (Wed, Feb 3)
Xoma offering $21 million in stock and warrants
AP (Wed, Feb 3)
Medivation's Alzheimer Trial Data in Early March: Biobuzz
at TheStreet.com (Wed, Feb 3)
XOMA LTD /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
EDGAR Online (Wed, Feb 3)
XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants
GlobeNewswire (Wed, Feb 3)
XOMA Reviews Priorities for 2010 and 2009 Accomplishments
GlobeNewswire (Tue, Jan 19)
More Headlines for XOMA...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.05
EPS Est (in 2 years) (Dec-10) :-0.13
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies and other agents to treat inflammatory, autoimmune, infectious, and oncological diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices